CRISPR, Gene Therapies, and Cure Pricing Conundrums
Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Motley Fool Hidden Gems Investing
See all episodes →
The Bond Market Selloff is Showing up in Earnings Reports
Berkshire Hathaway Hasn’t Done This in Over 3 Years
Mastercard CEO: AI Shopping Agents, Machine-to-Machine Payments, and the New Infrastructure of Commerce
Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Longevity: Can We Add Another 30 Years? | The Decade Ahead
#303: The AI Stocks No One is Talking About: Biotech Boom
Netflix Shares Drop After Earnings, and the Top Biotech Analyst Dissects the Race for a COVID Cure
James van Geelen on Thematic Investing Right Now
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.